Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Iovance Biotherapeutics, Inc.
< Previous
1
2
Next >
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 16, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
August 08, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
July 29, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 19, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
June 28, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
June 21, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
May 24, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
May 23, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 17, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
May 09, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
May 01, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at Upcoming Conferences
April 30, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
April 24, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 19, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 22, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
March 04, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at Upcoming Conferences
March 01, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
February 28, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
February 22, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
February 20, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
February 16, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
February 16, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
February 16, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
January 19, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
December 27, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 22, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 17, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
November 07, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
October 31, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
October 31, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.